Liraglutide Suppresses Obesity and Hyperglycemia Associated with Increases in Hepatic Fibroblast Growth Factor 21 Production in KKAy Mice
Figure 1
The effects of intraperitoneal injection of liraglutide (150 μg/kg) or saline on (a) food intake, (b) body weight, (c) blood glucose levels, (d) plasma insulin, (e) glucagon, and (f) Fgf21 levels in individually housed mice are determined 24 h after treatment, as described in the Materials and Methods section. Basal body weight in 6-week-old mice treated with or without liraglutide was g and g, respectively. The data are presented as the mean ± SEM ( for each group). .
